We picked up on an advertisement from the Cardiovascular Research Foundation for the seventh International Conference on Cell Therapy for Cardiovascular Disease. January 25-27, 2012 in New York. What struck is the lineup of the companies and panelists and the implications for the cardiovascular companies in the space, such as Baxter, Cytori, MesoBlast, NeoStem.
What caught our eye is the panel on the second day, "Acute Injury: STEMI and NSTEMI". The panel will be moderated by some very well-known KOL's such as Henricus J. Duckers, Gregg W. Stone, Andreas M. Zeiher. Dr Zeiher is one of the founders of a German private company also working on a cell based therapy (cells that follow an ischemic gradient) for AMI. Cytori will talk about the PRECISE trial (Adipose (from fat) stem cells for chronic ischemia. Dr. Doug Losorodo (who is not the principal investigator in the Baxter phase III trial) which uses CD 34+ cells (just like NeoStem (NBS) Amorcyte trial) will also present on the following panel which will review CLI (Critical limb ischemia) and CMI (Chronic Myocardial Ischemia). Even Dr. Robert Bolli who was recently features on CBS talking about his myocytes that repair dead heart muscle will be a panelist.
Our take away message: When we see Baxter and other prominent researchers now talking in these forums , presenting data and defined mechanisms of action, it raises our confidence level that proof of concept from trials is not far behind. Watch the work that NeoStem (NBS) is doing in AMI as a value play versus Baxter (BAX) with a very similar therapeutic approach. Doug Losordo (PI Baxter) has been working in the space for 20 years and adds a measure of credibility as do the entire panel members.
Link to the Conference web site: http://celltherapy.crf.org/home.html
=============================
Day 2 Panel Agenda
=============================
Acute Injury: STEMI and NSTEMI
8:30 am - 9:55 am
Moderators: Henricus J. Duckers, Gregg W. Stone, Andreas M. Zeiher
8:30 am
Trial I. Long-term FU of Patients with an AMI Treated with Adipose-Derived Stem Cells (APOLLO)
Henricus J. Duckers
8:40 am
Trial II. LATE-TIME and Others
Stephen G. Ellis, Timothy D. Henry
8:50 am
Trial III. MAPC Results and Directions
Marc S. Penn, Warren Sherman
9:00 am
Trial IV. TBA
Raj Makkar
9:10 am
EPTS
Henricus J. Duckers, Marc S. Penn
9:25 am
Discussion
Break
9:55 am - 10:25 am
CLI/CMI
10:25 am - 12:00 pm
Moderators: Francisco Fernandez-Aviles, Amit Patel
10:25 am
Trial I. CD34+ Cells for Refractory Angina
Douglas W. Losordo
10:35 am
Trial II. Adipose-Derived Cells for Chronic Ischemia: The PRECISE Trial
Francisco Fernandez-Aviles
10:45 am
Trial III. Update on Standardization of CD133 Intramyocardial BMSC
Gustav Steinhoff
10:55 am
Trial IV. BMAC for CLI: Status of a Phase 3 Trial
Thomas F. O'Donnell
11:05 am
Trial V. Placenta-Derived Cells for CLI
Christof Stamm
11:15 am
Abstract Presentation
11:20 am
EPTS
Timothy D. Henry, Amit Patel
11:35 am
Discussion
Lunch
12:00 pm - 1:00 pm
Heart Failure and Chronic Disease
1:00 pm - 2:30 pm
Les Miller
1:00 pm
Trial I. SCIPIO
Roberto Bolli
1:10 pm
Trial II. Cell Wave
Andreas M. Zeiher
1:20 pm
Trial III. SDF-1 and SDF-2
Marc S. Penn
1:30 pm
Trial IV. Cardiocyte-Driven Bone-Marrow Precursors
Jozef Bartunek
1:40 pm
Trial V. MPC's for Ischemic and Non-Ischemic Heart Failure
Emerson C. Perin
1:50 pm
EPTS
Jozef Bartunek, Randall J. Lee, Amit Patel
2:05 pm
Discussion